| Bioactivity | NS13001 is a potent, selective, orally active allosteric positive modulator of SK channels (small conductance calcium-activated potassium channels). The EC50s are 1.8 and 0.14 μM for SK2 and SK3, respectively. NS13001 holds promise as a potential therapeutic agent for treatment of spinocerebellar ataxia type 2 (SCA2) and possibly other cerebellar ataxias[1]. | ||||||||||||
| Target | EC50: 1.8 μM (SK2), 0.14 μM (SK3) | ||||||||||||
| Name | NS13001 | ||||||||||||
| CAS | 1063331-94-1 | ||||||||||||
| Formula | C17H16ClN7 | ||||||||||||
| Molar Mass | 353.81 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kasumu AW, et al. Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2. Chem Biol. 2012 Oct 26;19(10):1340-53. |